Today, data is being created, exchanged, and collected like never before. It’s embedded in everything we do, whether we’re exchanging information with a friend, planning a trip, or putting a person on the moon. Our world runs on this ever-expanding network of information and, considering global data creation is projected to grow to more than 180 zettabytes by 2025, there are no signs of this trend slowing down.
Clinical data is at the forefront of this data explosion, with the amount of clinical data used per trial increasing by 183%. More data coming from multiple sources feeding into different data systems has made clinical trial management and oversight wildly complex.
The traditional Clinical Trial Management System (CTMS) was designed to view and keep data within the walls of either the sponsor, the Clinical Research Organization (CRO) or data vendors. Historically a CTMS was able to sufficiently handle clinical trial data as there were fewer data sources. However, the proliferation of data sources and the rise of outsourced trials changed how CTMS is defined, and called into question whether they are fit for purpose in today’s world.
How can our industry adapt and maximize the potential benefits of greater data availability? It’s important to first understand the evolution of CTMS and its role in modern-day clinical trials to chart the best path forward for your organization. From there, we can turn an eye toward the future of clinical trial management and oversight and review, scrutinize and define how teams can improve their ability to collect, analyze, and act on operational analytics insights.